Maximus Keeps Quarterly Dividend at $0.33 a Share, Payable June 1 to Shareholders of Record on May 15
Maximus, Inc. announced it will maintain its quarterly dividend at $0.33 per share. The dividend is scheduled to be paid on June 1, 2026, to shareholders who are on record as of May 15, 2026. This news was published on Marketscreener.
Maximus Declares Quarterly Cash Dividend of $0.33 per Share
Maximus (NYSE: MMS) announced that its Board of Directors has approved a quarterly cash dividend of $0.33 per share. The dividend is payable on June 1, 2026, to shareholders of record on May 15, 2026. Maximus is a leading provider of government services, helping to improve the delivery of public services through tech-enabled solutions.
Maximus declares $0.33 quarterly dividend | MMS Stock News
Maximus (NYSE: MMS), a government services provider, announced that its Board of Directors has approved a quarterly cash dividend of $0.33 per share. This dividend is payable on June 1, 2026, to shareholders of record as of May 15, 2026. The company emphasizes its role as a strategic partner to government agencies, aiming to improve public service delivery through tech-enabled solutions.
MMS Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes the financial performance of Maximus Inc (MMS), detailing its revenue breakdown, profitability margins, and a comparison with competitors. Maximus Inc generates most of its revenue from U.S. Federal Services and maintains a gross margin of 22.18%. The analysis also benchmarks MMS against rivals like STNE and NAMS regarding gross margin to assess its market position.
Maximus Ranked #7 on the Financial Times’ List of The Americas’ Fastest Growing Companies 2026
Maximus, a performance medicine telehealth company, has been ranked #7 on the Financial Times' list of The Americas’ Fastest Growing Companies 2026. The company, founded in 2020, offers online treatment protocols for testosterone optimization, GLP-1 weight loss, hair regrowth, and peptide therapies, reflecting the rapid expansion of performance medicine. This recognition highlights Maximus's success in a growing sector that focuses on proactive health optimization through a direct-to-consumer telehealth model.
Maximus Ranked #7 on the Financial Times’ List of The Americas’ Fastest Growing Companies 2026
Maximus, a performance medicine telehealth company, has been ranked #7 on the Financial Times' list of The Americas' Fastest Growing Companies 2026. The company, founded in 2020, offers online treatments for testosterone optimization, GLP-1 weight loss, and peptide therapies, highlighting the rapid expansion of performance medicine within American healthcare. This recognition underscores the significant demand for proactive health optimization solutions delivered through a direct-to-consumer telehealth model.
Allspring Global Investments Holdings LLC Sells 111,017 Shares of Maximus, Inc. $MMS
Allspring Global Investments Holdings LLC significantly reduced its stake in Maximus, Inc. by selling 111,017 shares in the fourth quarter, though institutional investors still hold a substantial portion of the company's stock. Despite this, company insiders, including the CFO and CEO, increased their holdings through recent stock purchases. Maximus also reported exceeding Q4 earnings expectations, raised its quarterly dividend, and provided optimistic EPS guidance for FY2026.
MAXIMUS, Inc. Stock Plummets to New 52-Week Low of $62.51
MAXIMUS, Inc. (MAXIMUS) has hit a new 52-week low of $62.51, representing a 26.01% stock price decline over the past year, contrasting with the S&P 500's 16.73% performance. Despite strong management efficiency evidenced by a 21.64% ROE and 15.51% ROCE, the company faces challenges with negative operating cash flow, a high debt-equity ratio, and trading at a premium compared to its peers' historical valuations. The market capitalization stands at USD 3,903 million with a P/E ratio of 10.00.
Maximus (NYSE:MMS) Hits New 1-Year Low - What's Next?
Maximus (NYSE:MMS) recently hit a new 52-week low of $62.51, trading below its moving averages, despite marginally beating EPS estimates but experiencing a revenue decline. Management issued strong FY2026 EPS guidance that significantly exceeds analyst forecasts, and the company has increased its quarterly dividend and seen insider buying from its CEO and CFO, indicating confidence in future performance. Analyst ratings are mixed, with one strong buy and one hold rating, while institutional investors have adjusted their positions.
MAXIMUS, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility
MAXIMUS, Inc. has undergone a stock evaluation revision amidst significant market volatility, with its stock currently priced at $65.09. The company has underperformed the S&P 500 across weekly, monthly, and year-to-date returns, experiencing declines of -4.83%, -13.91%, and -24.59% respectively. Technical indicators like MACD, Bollinger Bands, and moving averages signal a bearish sentiment for the small-cap company.
How Maximus and Skyral Bring Digital Twin Innovation to Federal Operations
Maximus is integrating Skyral's advanced digital twin technology into federal operations, particularly in defense, civilian, and healthcare sectors. This partnership allows federal agencies to simulate complex systems like workforce coverage and resource allocation using real-world data and AI, helping them make better, data-driven decisions and improve service delivery before implementing changes. The collaboration aims to accelerate the adoption of innovative technologies in the federal government while ensuring compliance and security.
Top General Counsels & Compliance Execs to Watch in 2026: Maximus' Elizabeth Moellering
Elizabeth Moellering, Interim General Counsel and Deputy General Counsel at Maximus, has been recognized as a top General Counsel to watch in 2026. She significantly improved the company's litigation function, reducing legal spend by over 30%, and is now focused on cybersecurity, emerging technology, and contract continuity. Moellering, praised by CEO Bruce Caswell for her leadership and legal acumen, emphasizes integrity and building legal teams that act as strategic business partners.
Maximus Inc Stock: Leader in Government Services Faces Sector Headwinds Amid Mixed Results
Maximus Inc, a government services company, faces challenging market dynamics despite its stable government-backed revenue model. The company reported softer financial performance in Q4 2025 due to sector headwinds like budget constraints, though it maintains a strong backlog of contracts. Maximus continues to invest in digital transformation and benefits from policy tailwinds, making it a defensive stock for North American investors.
User Clip: Bruce Caswell, President of Maximus Inc., on Health Care Law Implementation
This C-SPAN user clip features Bruce Caswell, President of Maximus Inc., discussing the implementation of health care law. Maximus Inc. is a government contractor that provides health and human services programs. The video likely delves into the operational aspects and challenges of rolling out new health care legislation from a corporate perspective.
Why Maximus (MMS) Is Down 5.0% After Weak Quarter And Cut Guidance - And What's Next
Maximus (MMS) recently reported a weak quarter with revenue down 4.1% year-on-year and cut its full-year guidance, missing analyst expectations. Despite these setbacks, the company highlights a strong pipeline of government contracts and expanding opportunities. While the market reacted negatively, the long-term investment narrative for Maximus relies on sustained demand for outsourced government services, with execution on new contracts being crucial for future growth.
Government & Technical Consulting Stocks Q4 Teardown: Maximus (NYSE:MMS) Vs The Rest
The article provides a Q4 2023 teardown of government & technical consulting stocks, focusing on Maximus (MMS) and comparing its performance to other key players like Booz Allen Hamilton (BAH), UL Solutions (ULS), Amentum (AMTM), and Jacobs Solutions (J). It highlights that the sector experienced a slower Q4, though it is poised for long-term growth due to increasing demand for cybersecurity, AI-driven solutions, and sustainability consulting. Maximus reported a weaker quarter with revenues falling short of expectations, leading to a significant stock drop, while Jacobs Solutions had the strongest performance with the biggest analyst estimates beat and fastest revenue growth.
MAXIMUS, Inc. Hits New 52-Week Low at USD 64.67
MAXIMUS, Inc. has reached a new 52-week low, trading at USD 64.67, representing a 23.02% decline over the past year. Despite a market capitalization of USD 3,903 million and strong management efficiency with high ROE and ROCE, the company faces challenges such as negative operating cash flow and a high debt-equity ratio. This performance contrasts with the S&P 500's 11.87% increase over the same period.
Why Maximus (MMS) Is Down 5.0% After Weak Quarter And Cut Guidance - And What's Next
Maximus (NYSE: MMS) experienced a 5.0% stock drop following a weak quarterly revenue report, which was 4.1% down year-on-year, and reduced full-year guidance that missed analyst expectations. Despite these setbacks, the company highlights a strong pipeline of government contracts and expanding opportunities, with execution on these upcoming projects being crucial for its future performance. The article suggests that investors need to weigh the potential for long-term demand in outsourced government services against the immediate risks of contract and volume volatility, while also noting Maximus's use of AI for program integrity.
Government & Technical Consulting Stocks Q4 Teardown: Maximus (NYSE:MMS) Vs The Rest
This article analyzes the Q4 performance of several government and technical consulting stocks, focusing on Maximus (NYSE:MMS) and comparing it to peers like Booz Allen Hamilton (NYSE:BAH), UL Solutions (NYSE:ULS), Amentum (NYSE:AMTM), and Jacobs Solutions (NYSE:J). The sector experienced a softer Q4 with most companies missing revenue estimates, leading to an average 11.3% decline in share prices since earnings reports. Maximus reported lower revenues and significant misses in guidance, while Jacobs Solutions showed the strongest performance with beat on analyst estimates and revenue growth.
-1.42% for Maximus stock as sellers dominate below all key moving averages
Maximus stock (MMS) dropped 1.42% to $65.09, trading below all key moving averages and indicating persistent bearish trends. Technical indicators like MACD, ADX, RSI, Stoch RSI, and CCI all signal strong selling pressure and oversold conditions. The price is expected to consolidate between $64.80 and $67.80, with further declines possible if support at $64.80 is breached.
Maximus Inc stock hits 52-week low at 64.66 USD By Investing.com
Maximus Inc (NYSE: MMS) stock has reached a 52-week low of $64.66, representing a 35% drop from its high and a 23% year-to-date loss. Despite this, InvestingPro analysis indicates the stock is undervalued with a P/E ratio of 10, and analysts maintain optimistic price targets between $95 and $125. The company recently reported mixed first-quarter fiscal year 2026 earnings, exceeding EPS expectations but missing revenue targets.
MAXIMUS, Inc. Forms Death Cross, Signaling Potential Bearish Trend Ahead
MAXIMUS, Inc., a small-cap company, has formed a Death Cross, which typically indicates a potential bearish trend. The stock has experienced a significant year-to-date decline of 22.23% compared to the S&P 500's 4.22% drop, with various technical indicators also signaling bearish sentiment. Investors are advised to monitor these developments due to potential increased volatility and further declines.
Maximus Inc stock hits 52-week low at 64.66 USD By Investing.com
Maximus Inc's stock recently hit a 52-week low of $64.66, representing a 35% drop from its high and a 23% year-to-date loss. Despite this, InvestingPro analysis suggests the stock is undervalued with a P/E ratio of 10, and analysts maintain optimistic price targets between $95 and $125. The company recently reported mixed Q1 2026 earnings, exceeding EPS expectations but missing revenue forecasts.
Vanguard disaggregates holdings; reports 0 shares of Maximus (MMS)
The Vanguard Group filed an amended Schedule 13G/A, announcing that it now holds 0 shares of Maximus Inc. (MMS), equating to a 0% beneficial ownership. This change is due to an internal realignment and disaggregation of Vanguard subsidiaries for SEC reporting purposes, as stated in the filing. The company previously held voting and dispositive power over a certain percentage of Maximus stock but has since divested all holdings following this internal restructuring.
After Plunging 12.7% in 4 Weeks, Here's Why the Trend Might Reverse for Maximus (MMS)
Maximus (MMS) stock has recently experienced a 12.7% decline over four weeks, placing it in oversold territory with an RSI of 27.8. This technical indicator, combined with a 0.4% increase in the consensus EPS estimate for the current year and a Zacks Rank #2 (Buy), suggests a potential trend reversal and rebound for the stock. Investors may find this an opportune time to consider entry for future appreciation.
Assenagon Asset Management S.A. Purchases Shares of 181,565 Maximus, Inc. $MMS
Assenagon Asset Management S.A. acquired a new stake in Maximus, Inc. (NYSE:MMS) during Q4, purchasing 181,565 shares valued at approximately $15.7 million, bringing institutional ownership to 97.21%. Insider transactions included a director selling shares and the CFO buying shares. Maximus reported Q4 earnings that beat estimates, provided solid FY2026 guidance, and increased its quarterly dividend.
Maximus, Inc. $MMS Shares Purchased by JPMorgan Chase & Co.
JPMorgan Chase & Co. has increased its stake in Maximus, Inc. (NYSE:MMS) by 19.8% in Q3, now owning 200,331 shares valued at approximately $18.3 million. Maximus reported Q3 EPS of $1.85, beating estimates, despite a 4.1% revenue decrease, and raised its quarterly dividend to $0.33 per share. Institutional investors hold a significant 97.21% of the stock, while the company's CFO recently purchased additional shares.
Assessing Maximus (MMS) Valuation As Shareholder Returns Lag Recent Revenue And Earnings Growth
Maximus (MMS) stock has experienced negative returns recently despite consistent annual revenue of US$5.37 billion and net income of US$371.78 million with modest growth. The company is considered undervalued, trading at $68.39 against a narrative fair value of $110, driven by investments in digital, AI, and an expanded pipeline. Future valuation could be impacted by government agencies' automation acceleration or changes in contract volumes.
Maximus Inc stock surges on strong Q4 earnings amid government services boom
Maximus Inc reported strong Q4 fiscal 2026 earnings, surpassing Wall Street expectations with an 8.2% revenue increase to $1.32 billion and adjusted EPS of $1.12. The stock surged 7.4% on optimism driven by expanded federal contracts, a record $25 billion backlog, and disciplined cost management. The company's stability and growth in government health and human services make it an attractive non-cyclical investment, especially for DACH investors seeking steady US exposure.
Maximus Inc stock surges on strong Q4 earnings and government services contract wins amid US budget
Maximus Inc (MMS) stock rose sharply after reporting stronger-than-expected Q4 results, with revenue reaching $1.3 billion and adjusted EPS of $1.12. The company secured $520 million in new federal contracts, boosting its backlog to a record $8.5 billion. This performance, driven by demand for health and human services outsourcing and increased US government spending, highlights Maximus's stable position in public sector outsourcing, offering defensive growth for investors.
Is Maximus (MMS) Pricing Misaligned After Recent Share Weakness And Solid DCF Outlook
Maximus (MMS) shares have experienced recent weakness, but a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 58.6% with an intrinsic value of $166.95 per share compared to its recent price of US$69.11. The company's P/E ratio of 10.14x is also below its industry average and Simply Wall St's "Fair Ratio" of 19.81x, further indicating potential undervaluation. These findings come despite mixed share price performance over different timeframes, influenced by its government services contracts and renewal cycles.
Xerox, ASGN, Maximus, CoStar, and Ryan Specialty Stocks Trade Down, What You Need To Know
A combination of hot inflation data and escalating geopolitical tensions led to a market downturn, impacting stocks like Xerox, ASGN, Maximus, CoStar, and Ryan Specialty. The Producer Price Index (PPI) surged, and rising oil prices due to a Middle East conflict contributed to investor anxiety. The Federal Reserve's cautious stance on interest rates, citing slow inflation progress and global instability, further dampened hopes for aggressive monetary easing.
Xerox, ASGN, Maximus, CoStar, and Ryan Specialty Stocks Trade Down, What You Need To Know
Several stocks, including Xerox, ASGN, Maximus, CoStar, and Ryan Specialty, experienced declines in the afternoon trading session. This market downturn was attributed to a combination of higher-than-expected inflation data (Producer Price Index up 0.7% in February) and escalating geopolitical tensions in the Middle East, which drove Brent crude prices higher. The Federal Reserve maintained interest rates, citing an "uncertain" economic impact from the conflict and slower-than-hoped progress on inflation, leading investors to anticipate delayed monetary easing.
Maximus (MMS) director Jan Madsen sells 742 shares under 10b5-1 plan
Maximus (MMS) director Jan Madsen sold 742 shares of common stock at $72.25 per share on March 17, 2026, as part of a pre-scheduled 10b5-1 trading plan established in September 2024. Following this transaction, Madsen directly holds 20,794.822 shares. This sale is considered routine for liquidity rather than a reaction to recent company news.
Xerox, ASGN, Maximus, CoStar, and Ryan Specialty Stocks Trade Down, What You Need To Know
A combination of higher-than-expected inflation data for February, escalating geopolitical tensions in the Middle East, and a cautious stance from the Federal Reserve led to a stock market downturn, impacting several companies including Xerox, ASGN, Maximus, CoStar, and Ryan Specialty. The Producer Price Index surged more than anticipated, signaling persistent inflation, while rising oil prices due to Mideast conflict added to investor anxiety. The Fed maintained interest rates, tempering hopes for aggressive monetary easing and contributing to a broad market selloff.
Real world experience drives modernization insight, Maximus asserts
Maximus has appointed David Crowson, an expert with extensive experience in state eligibility operations and technology modernization, to bring real-world insight to its public sector initiatives. Crowson's background includes working as a state eligibility worker and an agency CIO, offering a practical perspective on the challenges of updating government systems. This appointment highlights Maximus's commitment to integrating operational expertise with digital innovation for enhanced public sector transformation and patient care.
Director Jan Madsen Sells Shares of Maximus Inc (MMS)
Maximus Inc (MMS) Director Jan Madsen sold 742 shares of the company on March 17, 2026, reducing his total holdings to 20,794.822 shares. Over the past year, Madsen has sold 3,181 shares and made no purchases. Maximus Inc stock is considered modestly undervalued with a price-to-GF-Value ratio of 0.75, trading at $72.25 with a market cap of $3.932 billion and a P/E ratio of 10.97.
[144] MAXIMUS, INC. SEC Filing
This SEC Form 144 filing for MAXIMUS, INC. (MMS) details the proposed sale of 742 shares of common stock, acquired on March 16, 2026, through restricted stock vesting as compensation. The aggregate market value of these shares is $53,609.50, and the sale is to be executed on March 17, 2026, via Fidelity Brokerage Services LLC on the NYSE. The filing indicates a neutral impact and sentiment according to Rhea-AI.
Here’s Why Maximus Shares Are an Excellent Choice for Investors at This Time
Maximus is presented as an attractive investment due to its strong financial health, consistent earnings surprises, and positive growth outlook. The company recently increased its quarterly dividend and is leveraging AI to enhance the integrity of the SNAP program. Its favorable industry position further strengthens its investment appeal.
MAXIMUS, Inc. Experiences Evaluation Revision Amidst Mixed Market Signals and Performance Fluctuations
MAXIMUS, Inc. has revised its evaluation due to fluctuating market conditions, with its stock priced at $72.41 and a 52-week range of $64.68 to $100.00. Technical indicators show mixed signals, and its performance has varied significantly compared to the S&P 500, underperforming year-to-date but showing a positive return over one year. This adjustment reflects ongoing challenges in the market for the small-cap company.
Here’s Why Maximus Shares Are an Excellent Choice for Investors at This Time
Maximus (MMS) is presented as an attractive investment due to its strong financial health, consistent earnings surprises, and positive growth outlook. The company recently launched an AI-powered Accuracy Assistant for the SNAP program and increased its quarterly dividend, reflecting confidence in its future. With a Zacks Rank #2 (Buy) and a favorable industry position, Maximus is positioned for continued growth.
Here's Why Maximus Stock is a Great Pick for Investors Now
Maximus (MMS) is highlighted as an attractive investment due to its strong liquidity, consistent dividend payments, and positive growth prospects. The company recently launched an AI-enabled tool to improve the accuracy of the Supplemental Nutrition Assistance Program (SNAP) for states. Maximus also boasts a Zacks Rank of #2 (Buy), a positive earnings surprise history, and strong industry prospects.
Here's Why Maximus Stock is a Great Pick for Investors Now
Maximus (MMS) is considered a strong investment due to its new AI-enabled Accuracy Assistant for the Supplemental Nutrition Assistance Program (SNAP), its robust financial health, and commitment to shareholder returns through increased dividends. The company holds a Zacks Rank #2 (Buy), has a positive earnings surprise history, strong growth prospects, and a bullish industry rank. Other recommended stocks include Dave Inc. (DAVE) and FTI Consulting (FCN).
Dean Capital Management Purchases 13,941 Shares of Maximus, Inc. $MMS
Dean Capital Management increased its stake in Maximus, Inc. by 57.5%, now holding 38,183 shares valued at approximately $3.49 million, making the stock its 11th largest holding. Institutional investors collectively own about 97.21% of Maximus, while company insiders, including the CEO and CFO, have also recently purchased shares. Maximus reported Q4 EPS of $1.85, slightly above estimates, with a 4.1% revenue decline, and has set FY2026 EPS guidance and increased its quarterly dividend.
Maximus Inc Stock (ISIN: US5779331041) Faces Pressure Amid Government Services Slowdown
Maximus Inc stock is experiencing pressure due to mixed fiscal Q2 results, cautious guidance, and concerns over US federal spending uncertainties. Despite steady revenue growth, the company faces margin compression from higher operating costs and project delays. European investors exposed to US government contractors should note the risks associated with potential fiscal tightening.
Here's Why Maximus Stock is a Great Pick for Investors Now
Maximus (MMS) is presented as a strong investment pick due to its new AI tool, Accuracy Assistant, which helps states improve the Supplemental Nutrition Assistance Program (SNAP) accuracy. The company also demonstrates strong financial health with solid liquidity, a history of dividend payments, and an attractive Zacks Rank, positive earnings surprise history, and strong growth prospects. The article also suggests other top-ranked stocks, Dave Inc. (DAVE) and FTI Consulting (FCN), for investors' consideration.
Maximus Inc Stock (ISIN: US5779331041) Faces Pressure Amid Government Services Slowdown
Maximus Inc reported mixed fiscal Q2 results with steady revenue growth but compressed margins due to higher operating costs and project delays. The stock is facing selling pressure amidst investor concerns over US federal spending uncertainties ahead of the 2026 budget cycle, impacting European portfolios tracking US services exposure. Despite a robust backlog, the company faces risks from potential spending cuts and cost dynamics, though it maintains a resilient free cash flow and dividend.
MMS SEC Filings - Maximus 10-K, 10-Q, 8-K Forms
This page provides access to Maximus (MMS) SEC filings, including 10-K, 10-Q, and 8-K reports, offering investors and traders comprehensive regulatory information. It highlights specific filings such as an insider share increase by director Michael J. Warren and reports on quarterly earnings and material events. The platform also offers AI-powered summaries to help users understand complex documents and features real-time updates from EDGAR.
A Look At Maximus (MMS) Valuation After Recent Share Price Moves
Maximus (MMS) recent share price movements have drawn investor attention, with the stock closing at $73.75. The company is considered 33% undervalued, with a fair value pegged at $110, driven by its long-term government contracts and focus on digital transformation, workflow automation, and AI. However, this valuation depends on governments not insourcing more work and Maximus keeping pace with technological advancements in the public sector.
[Form 4] MAXIMUS, INC. Insider Trading Activity
MAXIMUS, INC. director Michael J. Warren reported an acquisition of 2,246 shares of Common Stock in the form of restricted stock units (RSUs) in a recent Form 4 SEC filing. These RSUs are set to vest one year from the grant date, and combined with prior dividend adjustments, Mr. Warren now directly holds 17,839.316 shares. The filing indicates a neutral impact and sentiment regarding this insider trading activity.
